CA2810119C - Clec14a inhibitors - Google Patents

Clec14a inhibitors Download PDF

Info

Publication number
CA2810119C
CA2810119C CA2810119A CA2810119A CA2810119C CA 2810119 C CA2810119 C CA 2810119C CA 2810119 A CA2810119 A CA 2810119A CA 2810119 A CA2810119 A CA 2810119A CA 2810119 C CA2810119 C CA 2810119C
Authority
CA
Canada
Prior art keywords
clec14a
inhibitors
inhibitor
individual
ribozyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2810119A
Other languages
English (en)
French (fr)
Other versions
CA2810119A1 (en
Inventor
Roy Bicknell
Xiaodong Zhuang
Manuela Mura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of CA2810119A1 publication Critical patent/CA2810119A1/en
Application granted granted Critical
Publication of CA2810119C publication Critical patent/CA2810119C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2810119A 2009-09-03 2010-09-03 Clec14a inhibitors Expired - Fee Related CA2810119C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23958409P 2009-09-03 2009-09-03
US61/239,584 2009-09-03
PCT/GB2010/001689 WO2011027132A1 (en) 2009-09-03 2010-09-03 Clec14a inhibitors

Publications (2)

Publication Number Publication Date
CA2810119A1 CA2810119A1 (en) 2011-03-10
CA2810119C true CA2810119C (en) 2018-10-23

Family

ID=43333027

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2810119A Expired - Fee Related CA2810119C (en) 2009-09-03 2010-09-03 Clec14a inhibitors

Country Status (8)

Country Link
US (1) US9255148B2 (https=)
EP (1) EP2473529B1 (https=)
JP (1) JP5962996B2 (https=)
AU (1) AU2010290989B2 (https=)
CA (1) CA2810119C (https=)
ES (1) ES2567030T3 (https=)
HU (1) HUE028878T2 (https=)
WO (1) WO2011027132A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013187556A1 (en) * 2012-06-14 2013-12-19 Scripps Korea Antibody Institute Novel antibody specific for clec14a and uses thereof
GB201501004D0 (en) * 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
CA3015162A1 (en) * 2016-03-15 2017-09-21 Cancer Research Technology Limited Antibodies and related molecules and uses thereof
JP2019515656A (ja) * 2016-03-15 2019-06-13 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ キメラ抗原受容体
KR102201992B1 (ko) * 2016-09-08 2021-01-12 주식회사 우리기술 clec14a에 특이적으로 결합하는 탈당화 항체 및 그 용도
CN113336830B (zh) * 2017-03-17 2023-07-07 浙江孚诺医药股份有限公司 肿瘤靶向多肽、制备方法及其应用
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
US5846220A (en) 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030092002A1 (en) 1997-09-17 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6225118B1 (en) 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
US6894148B2 (en) 1997-11-12 2005-05-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020015950A1 (en) 1999-07-07 2002-02-07 Karen Anne Jones Atherosclerosis-associated genes
PT1626058E (pt) * 1999-03-08 2008-02-15 Genentech Inc Composições e métodos para o diagnóstico de tumores
KR100510795B1 (en) 1999-08-31 2005-08-30 Compositions and Methods for the Treatment of Tumor
US7695959B2 (en) 2000-05-23 2010-04-13 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
ES2296829T3 (es) 2000-11-06 2008-05-01 Cancer Research Technology Limited Imaginologia, diagnostico y tratamiento de la enfermedad.
CA2438030A1 (en) * 2001-02-14 2002-10-10 Protein Design Labs Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20040033495A1 (en) * 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
WO2003101283A2 (en) * 2002-06-04 2003-12-11 Incyte Corporation Diagnostics markers for lung cancer
ATE462727T1 (de) 2002-11-20 2010-04-15 Cancer Rec Tech Ltd An menschliches roundabout bindende antikörper, polypeptide und ihre verwendung zur hemmung der angiogenese
US20060148695A1 (en) 2005-01-03 2006-07-06 National Cheng Kung University Novel angiogenic composition and use thereof
US8293710B2 (en) 2005-01-03 2012-10-23 Blue Blood Biotech Corp. Method for treating wounds using an EGF-like domain of thrombomodulin
AU2006223579A1 (en) * 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
BRPI0613227A2 (pt) * 2005-06-09 2011-01-04 Chiang Chuan Chi uma composição para cicatrização de ferida e uso desta

Also Published As

Publication number Publication date
WO2011027132A1 (en) 2011-03-10
HUE028878T2 (en) 2017-01-30
JP2013503842A (ja) 2013-02-04
US9255148B2 (en) 2016-02-09
EP2473529B1 (en) 2016-02-10
JP5962996B2 (ja) 2016-08-03
US20120276000A1 (en) 2012-11-01
AU2010290989B2 (en) 2016-05-19
ES2567030T3 (es) 2016-04-19
CA2810119A1 (en) 2011-03-10
EP2473529A1 (en) 2012-07-11
AU2010290989A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
IL260196A (en) Pirfenidone for use while avoiding cyp1a2 inhibitors instruction against taking or stopping them
WO2007143086A3 (en) Delivery method
MX2011013421A (es) Arnds formulado con lipido de direccionamiento del gen pcsk9.
PH12013502049A1 (en) Modulation of signal transducer and activator of transcription 3 (stat3) expression
TN2009000521A1 (en) Rnai inhibition of alpha-enac expression
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
EP4458361A3 (en) Modulation of ube3a-ats expression
CA2810119C (en) Clec14a inhibitors
IN2012DN00939A (https=)
IL210208A0 (en) Systems, devices, and methods for improving accuracy of biosensors using fill time
PH12014500956A1 (en) Pak inhibitor for the treatment of fragile x syndrome
WO2010120853A3 (en) Methods and compositions to detect and differentiate small rnas in rna maturation pathway
WO2009126650A3 (en) Inhibition of angiognesis
PH12013500554A1 (en) Process for preparing pan-cdk inhibitors of the formula (i) and intermediates in the preparation
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
WO2012065139A3 (en) Entpd5 inhibitors
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
BR112013002738A2 (pt) métodos e compostos para o diagnóstico e o tratamento do câncer
HK1253405A1 (zh) 用於治疗皮肤t细胞淋巴瘤(ctcl)的mir-155抑制剂
WO2009044153A3 (en) Inhibitors and uses
TW201129620A (en) New formaldehyde scavengers
WO2012139043A3 (en) Selective neuronal nitric oxide synthase inhibitors
WO2011083481A3 (en) Method for treatment of inflammatory disease and disorder
WO2012091496A3 (en) siRNA FOR INHIBITION OF Hif1α EXPRESSION AND ANTICANCER COMPOSITION CONTAINING THE SAME
GB2514285A (en) Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150806

MKLA Lapsed

Effective date: 20210903